Amycretin

Amycretin — which has since been assigned the international nonproprietary name zenagamtide — is Novo Nordisk's investigational, first-in-class unimolecular GLP-1 and amylin receptor agonist: a single molecule that activates both receptors, folding the amylin satiety pathway and the GLP-1 pathway into one agent (rather than combining two drugs as in CagriSema). After end-of-phase-2 regulatory feedback, Novo Nordisk announced in June 2025 that it would take both the once-weekly subcutaneous and once-daily oral formulations into Phase 3 for weight management, with initiation planned for the first quarter of 2026. By Novo's August 2026 half-year report, subcutaneous Phase 3 trials were underway — including AMAZE 8, a two-year head-to-head against semaglutide on body weight in people with overweight or obesity and type 2 diabetes, and HF-POLARIS, a heart-failure-with-obesity outcomes trial — while oral Phase 3 initiation was listed as an upcoming Q3 2026 milestone, and a separate Phase 3 program in type 2 diabetes is planned for the second half of 2026. Early data showed mean weight loss of 22.0% at 20 mg and 24.3% at 60 mg over 36 weeks subcutaneously (versus +1.9% and −1.1% in the corresponding placebo groups, estimates assuming all participants adhered to treatment) and 13.1% over just 12 weeks at the top oral dose (versus −1.2% on placebo). It is not approved and not commercially available anywhere as of August 2026; with Phase 3 trials only beginning in 2026, any approval remains years away.

Sources: Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development, Novo Nordisk, via GlobeNewswire (company release); Novo Nordisk Financial report for the period 1 January 2026 to 30 June 2026 (zenagamtide pipeline status), Novo Nordisk, via GlobeNewswire resource PDF (company filing); Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes — presented at ADA 2026, Novo Nordisk, via PRNewswire (company release); Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study, Dahl K. et al. (optional, non-blocking: complete list), Lancet, 2025; Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial, Gasiorek A. et al. (optional, non-blocking: complete list), Lancet, 2025

What is Amycretin and why does the GLP-1/amylin combination matter?

Amycretin adds amylin's satiety mechanism to GLP-1's appetite and glucose effects in a single molecule — amylin (the pathway behind cagrilintide and pramlintide) is a genuinely different lever that may deepen and sustain weight loss. Its dual oral/subcutaneous development is unusual and commercially significant.

What does the clinical evidence show?

Early-phase trials, published in The Lancet in June 2025, showed striking weight loss. In the subcutaneous Phase 1b/2a (125 adults with overweight or obesity), mean weight change at 36 weeks was −22.0% at 20 mg and −24.3% at 60 mg, versus +1.9% and −1.1% in the corresponding placebo groups — estimates assuming all participants adhered to treatment. In the oral first-in-human Phase 1 (144 participants), 12 weeks of daily tablets produced −10.4% at 50 mg and −13.1% at 2×50 mg, versus −1.2% on placebo. But these are early, relatively small, short studies, with Phase 3 still to confirm whether the curves hold. In type 2 diabetes, a 36-week randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial (262 adults on metformin, with or without an SGLT2 inhibitor; weekly subcutaneous doses up to 40 mg) reported HbA1c reductions up to 1.71 percentage points and weight loss up to 14.6% versus 2.1% on placebo — presented at the American Diabetes Association sessions in June 2026 under the compound's nonproprietary name zenagamtide; company-reported conference data, not yet peer-reviewed.

Sources: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study, Dahl K. et al. (optional, non-blocking: complete list), Lancet, 2025; Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial, Gasiorek A. et al. (optional, non-blocking: complete list), Lancet, 2025 · Evidence level: phase 1b/2a–Phase 2 (early); Phase 3 underway — not approved

What are the known side effects and safety concerns?

The most frequent reported effects were gastrointestinal, consistent with the GLP-1 component; the full safety profile is not yet established at Phase 3 scale. In the published Lancet trials, adverse events were mostly gastrointestinal, mild to moderate in severity, and had generally resolved by the end of the studies; no new safety signals were reported. Long-term and Phase 3 safety data do not yet exist (as of August 2026).

Sources: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study, Dahl K. et al. (optional, non-blocking: complete list), Lancet, 2025; Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial, Gasiorek A. et al. (optional, non-blocking: complete list), Lancet, 2025 · Evidence level: Early-phase

What is the regulatory status, and why is verification critical here?

Amycretin is investigational and not approved by the FDA, EMA, or any other regulator as of August 2026 — it is not available by any legitimate route outside Novo Nordisk's clinical trials — so any "amycretin" sold through research-chemical vendors is not from Novo Nordisk and is almost certainly counterfeit or mislabeled. For a compound this early and this in-demand, independent identity confirmation is the only meaningful check. See the legal status guide.

How does Peptigrity verify Amycretin?

Peptigrity collects independent third-party Certificates of Analysis for amycretin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Independent identity confirmation is the only way to know whether an unapproved, unavailable compound is what the label claims — and no independent amycretin lab tests are on file yet (verified August 2026). The trust score weights lab purity and reviews equally (50/50). See how to read lab results.

This section is for educational and informational purposes only and does not constitute medical advice. Amycretin (zenagamtide) is not approved by the FDA or equivalent regulators for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.

Frequently asked questions